Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -10 of 45 Show results per page	View Search Criteria \| Help With Results

Last Modified: 8/10/2007


1.		Phase III Master Protocol for Randomized Comparison of Single-agent Chemotherapy vs Standard Therapy with CAF (CTX/DOX/5-FU) in Previously Untreated Patients with Stage IV Breast Carcinoma --- Amonafide and Other Phase II Agents

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Completed				16 to physiologic 70				NCI				CLB-8642 CALGB-8642


2.		Study of Individualized Amonafide to Treat Prostate Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Completed				18 and over				Pharmaceutical / Industry				0001A2-200-US NCT00087854

Last Modified: 5/1/1988


3.		Phase II Chemotherapy with Amonafide for Patients with Stage III or IV non-Small Cell Lung Cancer (Summary Last Modified 05/88)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				18 and over				NCI				MSKCC-8739 NCI-T87-0098C, T87-0098

Last Modified: 10/1/1987


4.		Phase II Chemotherapy with Intravenous Amonafide in Patients with Extensive Small Cell Lung Cancer (Summary Last Modified 10/87)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over								CAN-NCIC-IND42 NCI-T87-0137O, T87-0137, IND42

Last Modified: 2/1/1989


5.		Phase II Chemotherapy with Amonafide in Patients with Unresectable or Metastatic Pancreatic Cancer (Summary Last Modified 02/89)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over				NCI				UCCRC-5019 NCI-T87-0149O, T87-0149

Last Modified: 4/1/1988


6.		Phase II Chemotherapy with Amonafide in Patients with Renal Cell Carcinoma (Summary Last Modified 04/88)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				18 and over				NCI				SWOG-8716

Last Modified: 10/15/2007


7.		Phase II Chemotherapy with Amonafide in Patients with Adenocarcinoma of the Prostate

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over				NCI				SWOG-8722

Last Modified: 12/1/1987


8.		Phase II Chemotherapy with Amonafide in Patients with Colorectal Carcinoma (Summary Last Modified 12/87)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				no age specified				NCI				SWOG-8714

Last Modified: 2/1/1989


9.		Phase II Chemotherapy with Amonafide in Patients with Pancreatic Adenocarcinoma (Summary Last Modified 02/89)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over				NCI				SWOG-8720

Last Modified: 2/1/1992


10.		Phase II Chemotherapy with Amonafide in Patients with Advanced Hormone-Resistant Cancer of the Prostate (Summary Last Modified 02/92)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				18 and over				NCI				ICC-87U2 NCI-T87-0152D, T87-0152

Select All on One Page


					1 2 3 4 Next >

| | | | | | | |

A Service of the National Cancer Institute